Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B. Malpas, Sifat Sharmin, Cavit Boz, Raed Alroughani, Serkan Ozakbas, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Jeannette Lechner-Scott, Jens Kuhle, Murat Terzi, Guy Laureys, Liesbeth Van Hijfte, Nevin John, Pierre Grammond, Francois Grand'MaisonAysun Soysal, Ana Voldsgaard Jensen, Peter Vestergaard Rasmussen, Kristina Bacher Svendsen, Ismael Barzinji, Helle Hvilsted Nielsen, Tobias Sejbæk, Sivagini Prakash, Morten Leif Munding Stilund, Arkadiusz Weglewski, Nadia Mubder Issa, Matthias Kant, Finn Sellebjerg, Orla Gray, Melinda Magyari, Tomas Kalincik*, MSBase Study GroupDanish MS Registry Study Group

*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

10 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis'. Sammen danner de et unikt fingeraftryk.

Neuroscience

Keyphrases